Enterovirus 71 caused a large outbreak in Taiwan in 1998 with 78 deaths, and smaller outbreaks recurred in 2000 and 2001. The outbreak was recognixed because of a large number of hand, foot, and mouth disease cases and the rapid deaths of children with the disease. Virologic and pathologic studies indicated that EV71 was the most important agent related to severe and fatal cases and that a neurogenic inflammatory response was involved in the pathogenesis of cardiopulmonary collapse resulting from fulminant EV71 infection. Thus, new antiviral drugs should be developed. DBPR-103 showed good PK profiles including high plasma concentration, low clearance rate, long half life, and medium oral bioavailability; also it showed high microsomal stability in metabolism study. DBPR-103 was further tested for oral activity in ICR mouse neonate model of lethal enterovirus infection: enterovirus 71 serotyupe strian 4643 MP4 infection in suckling mice. Treatment with DBPR-103 increased the survival ratre in mouse neonate model for therapeutic dosing regimens. In current status, DBPR-103 represents a promising new drug candidate for potential use in the treatment of human enterovirus infection.?
關聯:
Medicine in the 21st century Tri-Conference & Bio-Forum 2004?
